Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This prospective,multicenter, open-labe phase II study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of IV non-small cell lung cancer.
Epistemonikos ID: e89161d2f50fa92f306a9e571a67bd364830c6e8
First added on: May 08, 2024